CURX Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

Curanex Pharmaceuticals Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerCURX

Market Cap9.5M

Cash RunwayRunway 6-12 months

Next Catalystn/a

Public Research Snapshot

Curanex Pharmaceuticals Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for Traditional Use in China (Preclinical).

Pipeline

Asset	Indication	Modality	Stage	Public Note
Traditional Use in China	n/a	n/a	Preclinical	Public pipeline row
Preclinical Evaluation	n/a	n/a	Preclinical	Public pipeline row
Compound Identification	n/a	Small Molecule	n/a	Public pipeline row
Broad therapeutic potential	n/a	n/a	n/a	Public pipeline row
Potential for tolerability	n/a	n/a	n/a	Public pipeline row
COVID-19	six indications	n/a	Preclinical	Public pipeline row

Catalyst Preview

No public catalyst rows matched this view yet.

Cash Runway Preview

Estimated cash runway: Runway 6-12 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
No public trial rows are loaded yet.

Scientific Context

literature_publication | Five-year follow-up of the SABR-5 trial: primary toxicity analysis of stereotactic ablative radiotherapy for up to five oligometastases.
literature_publication | Lactic acid bacteria and endogenous ethanol mediate proton pump inhibitor-associated MASLD: a multicohort cross-sectional mediation analysis.
literature_publication | Structure-based calculation of excipient effects on the viscosity of concentrated antibody solutions.
literature_publication | Prednisolone modulates CD8⁺ and regulatory T-cell activity to dampen response to immune checkpoint inhibitor therapy in melanoma.
literature_publication | Lipid nanoparticles with aptamers enable targeted mRNA delivery to CD4⁺ T cells.

Want the full CURX research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.